Claritev price target lowered to $38 from $43 at Guggenheim

Guggenheim lowered the firm’s price target on Claritev (CTEV) to $38 from $43 and keeps a Buy rating on the shares. Claritev reported “solid” Q4 results and while 2026 revenue and EBITDA guidance “optically fell slightly short of expectations,” these can be explained away by conservatism on underlying topline drivers of the business and incremental investments via M&A flow-through and building out its international infrastructure, the analyst tells investors.